MedTrace Logo

Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336)

NCT00863109 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 133

Last updated 2017-04-07

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate the impact of chronic hepatitis C (CHC), and the treatment thereof with peginterferon alpha-2b (PEG) and ribavirin (RBV) according to standard clinical practice, on the health-related quality of life (HRQL) of a cohort of participants throughout 72 weeks of follow-up. HRQL was assessed using the 36-Item Short-Form Health Survey (SF-36) and the Chronic Liver Disease Questionnaire-Hepatitis C Virus (CLDQ-HCV).

Conditions

  • Hepatitis C, Chronic
  • Genotype 1
  • HCV-1

Interventions

BIOLOGICAL

Peginterferon alfa-2b (PEG)

Pegylated interferon alfa-2b was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).

DRUG

Ribavirin (RBV)

Ribavirin was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2013-05-31
Completion
2013-05-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00863109 on ClinicalTrials.gov